Network meta-analysis of 11 RCTs (n=8607) in adult SLE: anifrolumab (OR 1.78) and belimumab (OR 1.62) both beat placebo on SRI-4 with no significant difference between them; anifrolumab had higher BICLA response (OR 1.56) but more herpes zoster (OR 4.74).
Meta-analysisn = 8,607
Martinez-Martinez et al. Efficacy and safety of belimumab and anifrolumab in systemic lupus erythematosus: A systematic review and network meta-analysis